Thanks Redfloyd, the research reports read well and have been based on conservative assumptions which implies further upside from $1.47 as the chart below the NPV table shows. Obviously the Lodge report was done before Thomas Lonngren came onto the board (which is a massive coup considering he could have taken a job at any pharma/bio-tech in the world but chose CBio... i wonder why?) so i'm looking forward to the next Lodge update.
From my reading on previous RA deals CBio will prob end up doing a much larger deal than the wise-owl report uses for the $1.47 target valuation which means again even more upside.
With phase 2 results around the corner i don't think there is a better or cheaper bio-tech out there, esp considering all the previous trials have had excellent results on safety efficacy etc. And with the aussie bio-tech sector finally coming alive it looks like the smart money is now getting behind CBio so i reckon this could be one of the real performers this year.
CBZ Price at posting:
48.6¢ Sentiment: Buy Disclosure: Held
